Baseline Characteristics | Coronary calcification below median (n = 25) | Coronary calcification above median (n = 26) | Total (N = 51) | P value | Missing data |
---|---|---|---|---|---|
Age, y (mean; SD) | 54.1 (12.7) | 63.2 (12.7) | 58.7 (13.4) | 0.014 | 0 |
Gender, male (n; %) | 15 (60) | 21 (80) | 36 (70.6) | 0.104 | 0 |
Duration of HD, d (mean; SD) | 144.6 (67.8) | 145.8 (55.7) | 145.2 (61.3) | 0.065 | 0 |
Coronary calcification score (mean; SD) | 102 (164.8) | 2520.9 (1563.8) | 1335 (1651) | <0.001 | 0 |
Calcium, mmol/L (mean; SD) | 2.3 (0.2) | 2.3 (0.3) | 2.3 (0.2) | 0.800 | 1 |
Phosphorus, mmol/L (mean; SD) | 1.8 (0.4) | 1.8 (0.6) | 1.8 (0.5) | 0.857 | 1 |
Albumin, g/L (mean; SD) | 39.4 (2.9) | 36.2 (5.2) | 37.8 (4.5) | 0.011 | 1 |
Alkaline phosphatase, U/L (mean; SD) | 99.0 (51.9) | 110.0 (44.5) | 104.2 (48.2) | 0.490 | 13 |
Glucose, mmol/L (mean; SD) | 8.8 (7.2) | 9.3 (6.9) | 9.0 (7.0) | 0.790 | 1 |
HbA1C (mean; SD) | 0.07 (0.02) | 0.07 (0.02) | 0.07 (0.02) | 0.716 | 28 |
C reactive protein, mg/L (mean; SD) | 5.5 (8.2) | 31.8 (46.1) | 19.3 (35.7) | 0.091 | 30 |
Intact PTH, pmol/L (mean; SD) | 104.5 (129.0) | 104.3 (83.0) | 104.4 (108.8) | 0.994 | 10 |
Uric acid, μmol/L (mean; SD) | 380.4 (75.5) | 372.8 (78.5) | 376.6 (76.1) | 0.750 | 9 |
URR (mean; SD) | 65.4 (16.1) | 66.2 (7.3) | 65.8 (12.3) | 0.834 | 2 |
Hemoglobin, g/L | 112.76 (12.30) | 119.69 (11.31) | 116.29 (12.20) | 0.041 | 0 |
Comorbidities | |||||
COPD (n; %) | 9 (36 %) | 6 (23 %) | 15 (29.4) | 0.311 | 0 |
Liver disease (n; %) | 2 (8 %) | 0 (0 %) | 2 (3.9) | 0.141 | 0 |
Diabetes (n; %) | 13 (52 %) | 18 (69 %) | 31 (60.8) | 0.208 | 0 |
Hypertension (n; %) | 23 (92 %) | 24 (92 %) | 47 (92.2) | 0.967 | 0 |
Systolic blood pressure, mmHg (mean; SD) | 147.6 (23.2) | 145.4 (22.7) | 146.5 (22.8) | 0.737 | 0 |
Diastolic blood pressure, mmHg (mean; SD) | 78.8 (15.9) | 80.2 (14.2) | 79.5 (14.9) | 0.742 | 0 |
Baseline Cardiovascular Disease | |||||
Myocardial infarction (n; %) | 4 (16 %) | 7 (27 %) | 11 (21.6) | 0.343 | 0 |
CABG (n; %) | 2 (8 %) | 3 (11 %) | 5 (9.8) | 0.671 | 0 |
Percutaneous coronary intervention (n; %) | 1 (4 %) | 5 (19 %) | 6 (11.8) | 0.091 | 0 |
Atrial fibrillation (n; %) | 2 (8 %) | 5 (19 %) | 7 (13.7) | 0.244 | 0 |
DVT (n; %) | 5 (20 %) | 0 (0 %) | 5 (9.8) | 0.016 | 0 |
Pulmonary embolism (n; %) | 4 (16 %) | 0 (0 %) | 4 (7.8) | 0.034 | 0 |
Cause of ESRD | |||||
Glomerulonephritis (n; %) | 11 (44 %) | 2 (8 %) | 13 (25.5) | 0.003 | 0 |
Polycystic kidney disease (n; %) | 2 (8 %) | 1 (4 %) | 3 (5.9) | 0.529 | 0 |
Diabetes mellitus (n; %) | 6 (24 %) | 12 (46 %) | 18 (35.3) | 0.098 | 0 |
Hypertension (n; %) | 5 (20 %) | 10 (38 %) | 15 (29.4) | 0.148 | 0 |
Other (n; %) | 1 (4 %) | 1 (4 %) | 2 (3.9) | 0.977 | 0 |
Medications | |||||
Calcium carbonate (n; %) | 17 (68 %) | 18 69 % | 35 (68.6) | 0.925 | 0 |
Sevelamer (n; %) | 1 (4 %) | 0 (0 %) | 1 (2.0) | 0.303 | 0 |
Bisphosphonates (n; %) | 1 (4 %) | 0 (0 %) | 1 (2.0) | 0.303 | 0 |
Warfarin (n; %) | 4 (16 %) | 5 (19 %) | 9 (17.6) | 0.762 | 0 |
Alfacalcidol (n; %) | 14 (56 %) | 9 (35 %) | 23 (45.1) | 0.125 | 0 |